Compare · LAB vs RVTY
LAB vs RVTY
Side-by-side comparison of Standard BioTools Inc. (LAB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LAB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $9.69B, about 26.5x LAB ($365.2M).
- Over the past year, LAB is down 23.0% and RVTY is down 7.8% - RVTY leads by 15.2 points.
- Both names hit the wire about 7 times in the past 4 weeks.
- RVTY has more recent analyst coverage (18 ratings vs 5 for LAB).
- Company
- Standard BioTools Inc.
- Revvity Inc.
- Price
- $0.93+0.80%
- $86.69+0.03%
- Market cap
- $365.2M
- $9.69B
- 1M return
- +1.00%
- -1.41%
- 1Y return
- -22.97%
- -7.79%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 7
- 7
- Recent ratings
- 5
- 18
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest LAB
- SEC Form DEFA14A filed by Standard BioTools Inc.
- SEC Form DEF 14A filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
- SEC Form 4 filed by Egholm Michael
- SEC Form 4 filed by Kim Hanjoon Alex
- SEC Form 4 filed by Mackay Sean
- SEC Form 10-K filed by Standard BioTools Inc.
- Director Casdin Eli was granted 52,991 shares, increasing direct ownership by 2% to 2,954,053 units (SEC Form 4)
- Director Cox Troy was granted 57,264 shares, increasing direct ownership by 18% to 376,586 units (SEC Form 4)
Latest RVTY
- SEC Form 8-K filed by Revvity Inc.
- Revvity Board Declares Quarterly Dividend
- SEC Form 4 filed by Gonzales Anita
- Revvity to Present at Upcoming Investor Conferences
- Revvity downgraded by Barclays with a new price target
- Revvity to Hold Earnings Call on Tuesday, May 5, 2026
- Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
- SEC Form 4 filed by Gonzales Anita
- SEC Form DEFA14A filed by Revvity Inc.
- SEC Form DEF 14A filed by Revvity Inc.